Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (RCKT)
NASDAQ:RCKT
Rocket Pharmaceuticals (RCKT) Stock Price & Analysis
855 Followers
RCKT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.89 - $32.53
Previous Close$22.82
Volume799.61K
Average Volume (3M)794.56K
Market Cap
$2.07B
Enterprise Value$1.77B
Total Cash (Recent Filing)$330.31M
Total Debt (Recent Filing)$25.95M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 07, 2024EPS Estimate
-$0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.87
Shares Outstanding90,782,211
10 Day Avg. Volume982,537
30 Day Avg. Volume794,558
Standard Deviation0.18
R-Squared0.10
Alpha0.00616
Financial Highlights & Ratios
Price to Book (P/B)5.41
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-768.39
Enterprise Value/Ebitda-9.50
Forecast
1Y Price Target
$45.86Price Target Upside100.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Rocket Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical DataKRESLADI demonstrated a robust 100% survival rate beyond 1 year and beyond age 2 in all patients treated, which is significant for LAD-I patients.
Financial PerformanceRocket’s stock has been impacted by the broader market’s weakness rather than any change in fundamentals, suggesting its current valuation is not reflective of its potential.
Regulatory ApprovalThe approval of Kresladi for severe leukocyte adhesion deficiency-I is anticipated, which could significantly boost the company's portfolio.
Bears Say
FDA RequirementsThe FDA issued a complete response letter (CRL) to Rocket's BLA for Kresladi, requesting more information related to CMC.
Regulatory SetbackRocket Pharma received a CRL from the FDA for KRESLADI, which was unexpected and disappointing.
Stock PerformanceThere is ongoing skepticism on the stock, with its performance down 23% year-to-date compared to a 1% decline in the broader market index.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
RCKT FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was $14.89 and its highest was $32.52 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Currently, no data Available
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is Aug 07, 2024 which is in 16 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on May 06, 2024. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.673 by $0.013.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -$0.72.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 90,782,210 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.673. Following the earnings report the stock price went up 0.69%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Among the largest hedge funds holding Rocket Pharmaceuticals’s share is Maverick Capital ltd. It holds Rocket Pharmaceuticals’s shares valued at 105M.
---
Rocket Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.86 (100.96% Upside)
$45.86 (100.96% Upside)
Blogger Sentiment
Bullish
RCKT Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 128.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $105.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.28%
12-Months-Change
Fundamentals
Return on Equity
-55.38%
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
RCKT Stock 12 Month Forecast
Average Price Target
$45.86
▲(100.96% Upside)
Technical Analysis
Best Analysts Covering RCKT
1 Year
1 Year Success Rate
15/22 ratings generated profit
1 Year Average Return
+31.27%
reiterated a buy rating 9 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +31.27% per trade.
---